Innovacell Inc.

Business Details

The Group is a single-segment company engaged in R&D of three autologous skeletal muscle-derived cell therapy pipelines (ICEF15, ICEF16, ICES13) targeting the incontinence field (fecal urge incontinence, fecal passive incontinence, and stress urinary incontinence). The company is currently in a pure R&D phase with zero business revenue from external customers, and its lead pipeline ICEF15 is undergoing an international Phase III joint clinical trial in Japan and Europe. Monetization is expected through license upfront payments, milestone payments, and product wholesale income, among others. The company listed on the TSE Growth Market in February 2026, substantially improving its financial base.

Recent Overview

Financial base substantially improved through TSE Growth Market listing; EIB venture debt fully repaid

The company listed on the TSE Growth Market on February 24, 2026, raising a total of ¥11,750 million through a public offering, third-party allotment, and conversion of ratchet-type stock acquisition rights. Using these proceeds, the company fully repaid on March 31, 2026 a total of ¥3,212 million (€17 million) in venture debt and accrued interest owed to the European Investment Bank (EIB), substantially improving net assets from -¥630 million at the end of the prior fiscal year to ¥10,194 million. The cumulative number of randomized patients in the ICEF15 Phase III trial increased to 222 (from 204 at the end of the prior fiscal year). As a subsequent event, the company resolved to issue restricted stock compensation (53,400 shares, issue price ¥685) to three directors.

Key Products

Growth Drivers

• Acceleration of patient enrollment in the ICEF15 Phase III international joint clinical trial (Fidelia trial) (222 patients achieved, target of 290 patients)
• Fundamental strengthening of the financial base through fundraising of ¥11,750 million via the TSE Growth Market listing (February 2026)
• Resolution of financial risk and turnaround to positive net assets (¥10,194 million) through full repayment of EIB venture debt
• Establishment of a commercialization structure through an exclusive wholesale distribution agreement with Alfresa for the Japanese domestic market
• Expansion to a tri-regional (Japan, US, Europe) structure through the commencement of discussions with the US FDA (Type B/C Meeting)
• Progress in European commercialization preparations through a term sheet agreement with a European commercialization services company
• Progress of the next-generation pipeline through preparations to initiate the ICEF16 Phase I/II clinical trial in 2026
• Regulatory framework development and market expansion in the regenerative medicine field, including the world's first approval of an iPS cell-derived regenerative medicine product in March 2026

Risks

• Structure in which zero business revenue is generated from external customers, with all future revenue dependent on regulatory approval and commercialization (the full-year business revenue forecast of ¥1,000 million has not yet been achieved)
• Risk of delayed patient enrollment or trial failure in the ICEF15 Phase III trial (222 patients against a target of 290, still unmet)
• Structure of continuous cash consumption, with -¥723 million recorded in Q1 against a full-year operating loss forecast of -¥3,337 million
• Estimated royalty payment amounts (based on future sales plans and other estimates) recorded as long-term borrowings, which could materially affect the financial statements if estimates are revised
• Foreign exchange and interest rate risk related to the long-term borrowings balance (¥1,564 million) of the overseas subsidiary Innovacell GmbH
• Complexity and scale-up risk in the manufacturing process for autologous cell therapy products
• Prolongation of regulatory approval processes and uncertainty of approval acquisition across Japan, the US, and Europe
• Risk of competitors obtaining approval ahead of the company for similar pipelines